Conduct↦Safety↦Safety Risk Review↦Aim
Was betrifft es? Warum ist das wichtig?
The SP-INV and Site-INV are responsible for the ongoing safety of their study participants, including study staff. They must ensure that risk-control measures remain effective and that new potential risks are promptly identified (e.g. risk identification). This can only be achieved through the execution of selective risk reviews.
Questions to address during study conduct include:
- Have any new risks been identified that were initially not anticipated?
- Have old risks become less or more relevant due to new situations or insight?
- Are current risk-control measures effective or must they be improved?
- Are risk-control measures still relevant with respect to emerging knowledge and expertise?
- Is study staff up-to-date and trained on current study risks including implemented control measures?
Risk reviews are interactive processes between those implementing risk-control measures, and those deciding which control measures to implement. Only through this communicative feedback loop can it be guaranteed that risk-control measures remain appropriate and effective.
Was muss ich befolgen?
As a SP-INV during study conduct, you are responsible to:
- Assess reported adverse events (e.g. IMP safety reporting, IMD safety reporting), including pre-defined safety parameters in accordance to the Safety Management Plan (SMP)
- Re-evaluate any study risks and risk-control measures defined at study start
- Identify any new potential study risks, including changes to existing risks
- Ensure that implemented risk-control measures remain relevant
- Regularly perform a risk-benefit assessment of your study. If applicable, update the study`s risk-benefit and SMP, and implement required steps
- Assess whether safety measures require an amendment of your study protocol, and/or the patient information sheet
- Document performed risk reviews and include any adaptations to your risk strategy
As a Site-INV:
- Implement and comply with safety reporting procedures and responsibilities
- Ensure staff is trained on study risks, defined risk-control measures, including potential adaptations
- Stay in ongoing contact with the SP-INV of the study regarding safety management and concerns
Wo kann ich Hilfe anfordern?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
Documents
External Links
Swissmedic – see in particular information sheets
- BM101_10_002e_MB FAQ on clinical trials with medicinal products
- BW101_10_003e_AA Instruction for reporting during the course of a study
- MU680_20_004e_MB Medical devices FAQs patients
References
ICH GCP E6(R3) – see in particular guidelines
- 2.7 2.7 Participant medical care and safety reporting
- 3.9 Sponsor oversight
- 3.10 Quality management
- 3.11 Quality assurance and quality control
- 3.13 Safety Assessment and Reporting
- Appendix B.9 Assessment of safety
ISO 14155:2020 Medical device (access liable to cost) – see in particular section
- 6.2 Risk Management
- 7.4 Adverse events and device deficiencies
- 9.2.5 Safety evaluation and reporting
- 10.8 Safety reporting